
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549


SCHEDULE 13G
(Rule 13d-102)

Information Statement Pursuant to Rules 13d-1 and 13d-2
Under the Securities Exchange Act of 1934
(Amendment No. 1)*


Repros Therapeutics Inc.
(Name of Issuer)

Common Stock
(Title of Class of Securities)


76028H100
(CUSIP Number)


September 29, 2008
Date of Event Which Requires Filing of the Statement

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

o	Rule 13d-1(b)
x	Rule 13d-1(c)
o	Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1.	NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Vermillion Asset Management LLC
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o (b) x
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware limited liability company
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		5.	SOLE VOTING POWER 1,911,800⁽¹⁾ shares
		6.	SHARED VOTING POWER 0
		7.	SOLE DISPOSITIVE POWER 1,911,800⁽¹⁾ shares
		8.	SHARED DISPOSITIVE POWER 0
9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,911,800⁽¹⁾ shares
10.	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) Approximately 12.60%⁽²⁾ as of the date of this filing
12.	TYPE OF REPORTING PERSON IA

(1)	Includes shares of Common Stock of the Issuer held by Cyan Opportunities Fund, Ltd., a Cayman Islands company (“Cyan”), as reported herein, and shares of Common Stock of the Issuer held by certain accounts managed by Vermillion Asset Management LLC, a Delaware limited liability company (“Vermillion”). Vermillion controls the voting and disposition of such shares.

(2)	Based on 15,174,904 outstanding shares of Common Stock of the Issuer, as reported in the Issuer’s Prospectus Supplement on Form 424(b)(5) filed with the Securities and Exchange Commission on September 29, 2008.

Item 1(a)	Name of Issuer:	Repros Therapeutics Inc.
1(b)	Address of Issuer’s Principal Executive Offices:

		2408 Timberloch Place, Suite B-7
		The Woodlands, Texas 77380

Item 2(a)	Name of Person Filing⁽⁴⁾
Item 2(b)	Address of Principal Business Office
Item 2(c)	Citizenship

	Vermillion Asset Management LLC
	267 Fifth Avenue, 7^th Floor
	New York, NY 10016
	Delaware limited liability company

	Cyan Opportunities Fund, Ltd.
	c/o Vermillion Asset Management LLC
	267 Fifth Avenue, 7^th Floor
	New York, NY 10016
	Cayman Islands company

(a)	o	Broker or dealer registered under Section 15 of the Exchange Act;

(b)	o	Bank as defined in Section 3(a)(6) of the Exchange Act;

(c)	o	Insurance company as defined in Section 3(a)(19) of the Exchange Act;

(d)	o	Investment company registered under Section 8 of the Investment Company Act;

(e)	o	An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

(f)	o	An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

(g)	o	A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

(h)	o	A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;

(i)	o	A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;

(j)	o	Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

(5)	See footnote 1 above.

(6)	See footnote 2 above.